Biopharma PEG Scientific Inc.

🌟 Exciting first day at #CPHI2024 Milan! 🌟 We've had an amazing first day at booth 3F81, with many visitors stopping by to learn about our PEG derivatives. Thank you to everyone who visited! We look forward to meeting you today or tomorrow if you haven't had the chance yet. Let's discuss how we can support your projects and goals. #CPHIMilan #Pharma #Biotech

✨ Join Us Tomorrow at Booth 3F81! ✨ We’re excited to meet you at the CPHI Milan! Stop by Booth 3F81 and connect with our team to discover our PEG derivatives. Don't miss the chance to explore how we can support your needs.

Ascendis Pharma announced that the U.S. Food and Drug Administration (FDA) has approved Yorvipath (palopegteriparatide, TransCon PTH,) injection as the First and Only treatment for adults with hyperparathyroidism. Palopegteriparatide is a prodrug consisting of a parent drug, PTH(1‐34), transiently conjugated to a branched methoxypolyethylene glycol (mPEG) carrier through a proprietary TransCon linker. This conjugate mimics or manipulates the effects of naturally occurring PTH, regulating calcium and phosphate and acting on the bone, kidney, and intestine. https://lnkd.in/gbzEgy7J

Biopharma PEG provides GMP-grade PEG derivatives from grams to 100 kilograms. Monodispersed PEGs: precise PEG units from 4 to 48. Polydispersed PEGs: molecular weight from 400 to 40K. Y-shaped PEGs: Y-shape PEG NHS Multi-arm PEGs: 4-arm PEGs, 8-arm PEGs Please feel free to contact us at [email protected] for more details. https://lnkd.in/gyBr69gX

Biopharma PEG offers GMP-grade PEG derivatives in quantities from grams to 100 kilograms. These PEG linkers are ideal for a wide range of applications, including PEGylation, LNP drug delivery, ADC therapy, PROTAC development, hydrogels, and diagnostics, etc. Join us at CPHI Milan 2024! 📅 Date:  8 - 10 October, 2024 📌 Location: Fiera Milano, Italy 📍 Booth No.: 3F81

Maximizing the effectiveness of antibody-drug conjugates (ADCs) requires the right components, and PEGs play a crucial role as linkers between antibodies and payload molecules. Using PEGs as linkers not only allows for higher ADC loading but also provides a protective shield that enhances solubility and stability. This approach reduces aggregation, which in turn lowers immunogenicity, improves pharmacokinetics, increases circulation time, and reduces toxicity. Biopharma PEG offers a wide range of PEG linkers to support your ADC development projects. Our PEG linkers boast over 95% purity and serve as the foundational building blocks for successful ADCs. Let's collaborate to elevate your ADC development to the next level! https://lnkd.in/gdXJcdY #BiopharmaPEG #ADCs #Biotechnology

🚀 Exciting Advances in Cancer Treatment: The Rise of Radionuclide Drug Conjugates (RDCs)! 🌟 https://lnkd.in/g3TM2TVg Radionuclide drug conjugates (RDCs) are revolutionizing cancer therapy by combining precise targeting with powerful cell-killing effects. These innovative treatments use specialized ligands to deliver radioactive agents directly to cancer cells, focusing radiation on tumors while sparing healthy tissues. The field of RDCs is advancing swiftly, with Novartis at the forefront. Since 2016, the FDA has approved nine RDC drugs, including seven for cancer diagnosis and two for treatment. These drugs primarily target PSMA and SSTR, two key markers in cancer cells. Notably, Lutathera and Pluvicto are leading the charge. In 2022 alone, these therapies generated impressive sales of $471 million and $271 million, respectively. As RDCs continue to evolve, they promise to offer even more targeted and effective options for cancer patients worldwide. Stay tuned for more breakthroughs in this exciting field! 🌐💊 #CancerTreatment #RDC #Innovation #Pharmaceuticals #Healthcare #Novartis #Lutathera #Pluvicto

🚀 Exciting Developments in Macrocyclic Peptide Drugs! In 2023, three macrocyclic peptides—Rezafungin, Motixafortide, and Zilucoplan—gained FDA approval, marking a significant milestone in peptide drug development. Macrocyclic peptides bridge the gap between small-molecule drugs and large biologics. They offer the best of both worlds, effectively targeting protein-protein interactions with the precision and stability needed for various treatments. Let's continue to watch this space as macrocyclic peptides shape the future of medicine! 🌟 #Pharmaceuticals #DrugDevelopment #Biotech #CancerResearch #InnovativeMedicine https://lnkd.in/grGNb-yh

Monodispersed PEGs are precisely sized polymers that enhance the stability and delivery of proteins and peptides in pharmaceuticals. Key in ADC and PROTAC linkers, they ensure precise drug release and targeted protein degradation. Discover monodispersed PEGs here that can revolutionize your therapeutic solutions. #ADC #PROTAC #PROTEIN #PEPTIDE #PEG https://lnkd.in/gbhdPW-n

Bruton's tyrosine kinase (BTK) inhibitors have shown significant clinical efficacy, but an unmet clinical need remains due to acquired resistance. To address the problem of drug resistance, many strategies have been developed. Many companies are engaged in developing BTK PROTACs to overcome resistance issues associated with BTK inhibitors. BTK PROTACs promote the degradation of BTK protein, bypassing multiple resistance mechanisms and enhancing drug efficacy.  https://lnkd.in/gZgWTCPY #PROTAC #BTK #drugresistance